New combo therapy aims to control multiple myeloma
NCT ID NCT04722146
First seen Nov 01, 2025 · Last updated May 03, 2026 · Updated 22 times
Summary
This early-stage study tests the safety and best doses of teclistamab when combined with other cancer drugs for people with multiple myeloma, a type of blood cancer. About 140 participants who have already tried other treatments will receive different drug combinations. The goal is to find safe and tolerable doses that can control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alfred Health
Melbourne, 3004, Australia
-
CHU Nantes
Nantes, 44093, France
-
CHU de Bordeaux - Hospital Haut-Leveque
Pessac, 33604, France
-
Calvary Mater Newcastle Hospital
Waratah, 2298, Australia
-
Centre Leon Berard
Lyon, 69373, France
-
Chu Rennes Hopital Pontchaillou
Rennes, 35000, France
-
Colorado Blood Cancer Institute
Denver, Colorado, 80218, United States
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202, United States
-
Institut Universitaire du cancer de Toulouse-Oncopole
Toulouse, 31059, France
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
-
Medical College Of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Memorial Sloan-Kettering Cancer Center
New York, New York, 10021, United States
-
St Vincents Hospital Melbourne
Fitzroy, 3065, Australia
-
Tennessee Oncology
Nashville, Tennessee, 37203, United States
-
The Christie Nhs Foundation Trust
Manchester, M20 4BX, United Kingdom
-
The Royal Marsden NHS Trust Sutton
Surrey, SM2 5PT, United Kingdom
-
UZ Gent
Ghent, 9000, Belgium
-
UZA
Edegem, 2650, Belgium
-
University College Hospital
London, NW1 2BU, United Kingdom
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
-
University of California San Francisco
San Francisco, California, 94143, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15232, United States
-
Washington University School Of Medicine
St Louis, Missouri, 63110-1032, United States
-
Weill Cornell Medical College
New York, New York, 10065, United States
-
Winship Cancer Institute Emory University
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.